Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

230.29
-34.6350-13.07%
Volume:1.08M
Turnover:254.54M
Market Cap:15.24B
PE:17.77
High:257.53
Open:256.25
Low:228.56
Close:264.92
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:7.66
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.19
PE(LYR):-52.13

Loading ...

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires Live
·
May 26

J.P. Morgan Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 20

Ascendis Pharma Initiated at Buy by Citigroup

Dow Jones
·
May 19

Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount

Simply Wall St.
·
May 19

Ascendis Pharma initiated with a Buy at Citi

TIPRANKS
·
May 19

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires Live
·
May 18

Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 18

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16

Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

TIPRANKS
·
May 15

Ascendis EVP Flemming Jensen sells 19,460 shares for $4.64 million

Reuters
·
May 13

Ascendis Pharma Is Maintained at Overweight by Barclays

Dow Jones
·
May 11

Ascendis Pharma price target raised to $345 from $342 at Barclays

TIPRANKS
·
May 11

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Becton Dickinson (BDX)

TIPRANKS
·
May 11

Ascendis Pharma (ASND) Gets a Buy from RBC Capital

TIPRANKS
·
May 08

Earnings Flash (ASND) Ascendis Pharma Posts Q1 Non-IFRS EPS 0.27 Euro

MT Newswires Live
·
May 07

Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Benzinga Earnings
·
May 07

Press Release: Ascendis Pharma Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Ascendis Pharma posts ApproaCH trial Week 104 subgroup data presentation on achondroplasia

Reuters
·
May 07

Ascendis says TransCon CNP boosts growth velocity in achondroplasia children in 2-year trial data

Reuters
·
May 07